Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc. is a pre-clinical biosciences company specializing in the development of selective 5-HT receptor agonists for the treatment of severe and life-altering diseases. Their portfolio includes 5-HT2C, 5-HT2A, and 5-HT2C/A medicines aimed at addressing epilepsy, pain, and neuropsychiatric conditions. The company generates revenue through collaborations with research institutions such as the National Institutes of Health, University of Texas Medical Branch, and Medical College of Wisconsin, focusing on the development of treatments for epilepsy, impulse control disorders, and other related conditions.